Gastrointestinal blood loss induced by bromfenac sodium, aspirin, and placebo

Clinical pharmacokinetics and pharmacodynamics of bromfenac

Bromfenac is a nonsteroidal anti-inflammatory drug whose peak plasma concentration is reached 0.5 hours after oral administration. Bromfenac binds extensively to plasma albumin. The area under the plasma concentration-time curve is linearly proportional to the dose for oral doses up to 150 mg. The relationship between the total plasma and analgesic effect has been established. Only small amounts of bromfenac are eliminated unchanged, with the remaining drug being biotransformed into glucuronide metabolites which are excreted in urine and bile. Rapid elimination occurs in healthy individuals (half-life 0.5 to 4.0 h). Renal disease, hepatic disease and aging alter the disposition kinetics of bromfenac, and dosage adjustment may be advisable. Bromfenac modestly decreases free phenytoin concentrations. Bromfenac can cause idiosyncratic hepatic toxicity and has been withdrawn by its manufacturer pending further investigation of these case reports.

Pharmacologic management of pain and inflammation in athletes

This article attempts to concisely present some of the scientific basis of the pharmacology of anti-inflammatory medications. The clinical use and application of anti-inflammatories is also addressed. The information is designed to assist the clinician to develop a sound approach in selecting the appropriate treatment plan for their patients.